Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420611 | 0.94 | CA1 (0.50) | PTGDR2CA1CA2MAPTCYP1A1 | |
| SCHEMBL13199251 | 0.84 | GRB2 (0.52) | KIF11RXRARXRBRXRG | |
| SCHEMBL21501142 | 0.81 | CA1 (0.48) | PTGDR2CA1CA2MAPTCYP1A1 | |
| SCHEMBL15957723 | 0.79 | GRB2 (0.49) | KIF11RXRARXRBRXRGSMN1; SMN2 | |
| SCHEMBL6454587 | 0.79 | ALDH1A1 (0.52) | PTGDR2NPC1RAB9AMAPT | |
| SCHEMBL6451094 | 0.79 | PTGDR2 (0.43) | PTGDR2ESR2KIF11NPC1RAB9A | |
| SCHEMBL9000492 | 0.79 | CYP2C9 (0.61) | PTGDR2KIF11NPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL27892361 | 0.79 | RAB9A (0.50) | NPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL27598900 | 0.79 | RAB9A (0.50) | NPC1RAB9A | |
| SCHEMBL13199203 | 0.78 | GRB2 (0.57) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852751-B2 | Difluorobutyric acid metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030139453-A1 | Difluorobutyric acid metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| EP-1265865-A2 | DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070693-A2 | DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139453-A1 | Difluorobutyric acid metalloprotease inhibitors | DPEP1, TMPRSS15, FAP | PTGDR2 769/4885ESR2 1279/4885CA1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.